Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design

Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.